Hemostatic Efficacy of Pathogen-Inactivated Blood Components.
Chicago, United States. In Semin Thromb Hemost, Jan 2016
UNASSIGNED: Pathogen inactivation (PI), or pathogen reduction technology, reduces the infectious risk of plasma and platelet transfusions, and also affects clotting factor activities and platelet viabilities.
Acquired bleeding disorders in the elderly.
Seattle, United States. In Hematology Am Soc Hematol Educ Program, Jan 2016
The hemostatic balance changes with advancing age which may be due to factors such as platelet activation, increase of certain clotting factor proteins, slowing of the fibrinolytic system, and modification of the endothelium and blood flow.
Emerging and future therapies for hemophilia.
New Brunswick, United States. In J Blood Med, 2014
In this brief review, the authors summarize data on EHL clotting factors, introduce agents whose mode of action is not clotting factor replacement, and list current gene therapy efforts.
Modern haemophilia care.
Malmö, Sweden. In Lancet, 2012
Early clotting factor concentrates were not sufficiently refined to enable self-administered treatment at home until the 1970s.
Nanoparticles for the delivery of genes and drugs to human hepatocytes.
Ibaraki, Japan. In Nat Biotechnol, 2003
When the gene encoding human clotting factor IX was transferred into the xenograft model using L particles, factor IX was produced at levels relevant to the treatment of hemophilia B. The yeast-derived L particle is free of viral genomes, highly specific to human liver cells and able to accommodate drugs as well as genes.